510TiP Camrelizumab combined with fruquintinib or regorafenib as second or later line therapy for BRAF positive-mutation advanced colorectal cancer (CRC) with microsatellite stability (MSS): A single-arm, phase II study
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI